Gemini Pharmaceuticals Limited
About Gemini Pharmaceuticals Limited
Data last updated:
Gemini Pharmaceuticals Limited is a public limited company based in Muzaffarnagar, Uttar Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 August 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN U24232UP2005PLC030446.
The company has an authorised share capital of ₹2.25 Cr and a paid-up capital of ₹2.2 Cr. It is led by directors including Sudhir Kumar and Ramdev.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 19 – A New Mandi, Muzaffarnagar, Uttar Pradesh, India – 251001.
As per the financials filed for FY 2023, the company reported a revenue of ₹6.31 Lakh, a decline of 23% compared to the previous year. For the same year it recorded a net profit of ₹3.88 Lakh (net margin 61.4%) and EBITDA of ₹4.64 Lakh (EBITDA margin 73.6%). Revenue has declined at a compounded annual rate (CAGR) of 14% over three years.
As per MCA filings, the company has open charges of ₹5.27 Cr on record. Court records list 9 cases involving the company, including 4 filed by the company and 5 filed against it; 1 case is pending.
The current compliance status is marked as active non-compliant by the Registrar of Companies.
Company details
Contact details
Gemini Pharmaceuticals Limited's registered office is in Muzaffarnagar, Uttar Pradesh. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address19 – A New Mandi, Muzaffarnagar, Uttar Pradesh, India – 251001
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Gemini Pharmaceuticals Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Gemini Pharmaceuticals Limited
FY 2025 filings availableGemini Pharmaceuticals Limited reported revenue of ₹6.31 Lakh (down 23% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 14% over three years, including a 23% fall in the latest year. EBITDA fell 28% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4.64 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹3.88 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 73.6% | ||||
| Net Profit Margin | 61.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Gemini Pharmaceuticals Limited, buy the company report.
Board of directors of Gemini Pharmaceuticals Limited
Gemini Pharmaceuticals has 4 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ramdev Also directs: Ravi Organics Limited, Divera Solutions Limited, Sunagro Insecticides Private Limited and 1 more | Additional Director | 25 Mar 2023 | 3 Years 7 Months | Current |
| Kuwar Singh Also directs: Ravi Organics Limited, Divera Solutions Limited, Sunagro Insecticides Private Limited and 3 more | Additional Director | 15 Apr 2016 | 10 Years 6 Months | Current |
| Sudhir Kumar Also directs: Divera Solutions Limited | Director | 01 Oct 2016 | 10 Years 0 Months | Current |
| Ajay Kumar Sharma Also directs: Ravi Organics Limited | Additional Director | 21 Feb 2012 | 14 Years 8 Months | Current |
Peer comparison
Gemini Pharmaceuticals Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sitesh Kavya Formulations Private Limited | ₹6.35 Lakh (FY 2016) | 1472.0% | Ranchi, Jharkhand, India | |||
| Himken Pharmaceuticals Private Limited | ₹6.35 Lakh (FY 2022) | -38.0% | Ahmedabad, Gujarat, India | |||
| Healthelixir Pharmaceuticals Private Limited | ₹6.34 Lakh (FY 2025) | 495.0% | Ghaziabad, Uttar Pradesh, India | |||
| Rangsubbs Pharmaceuticals (India) Private Limited | ₹6.34 Lakh (FY 2018) | Hyderabad, Telangana, India | ||||
| Galnmax Pharmaceuticals Private Limited | ₹6.32 Lakh (FY 2025) | 91.0% | Ajmer, Rajasthan, India | |||
| Gemini Pharmaceuticals Limitedthis company | ₹6.31 Lakh (FY 2023) | ₹3.88 Lakh | 61.4% | -23.0% | Muzaffarnagar, Uttar Pradesh, India | |
| Reinmed Pharmaceuticals Private Limited | ₹6.3 Lakh (FY 2023) | 1353.0% | Patna, Bihar, India | |||
| Alkem Wellness Limited | ₹6.3 Lakh (FY 2025) | Mumbai, Maharashtra, India | ||||
| East Initial India Pharmaceuticals Private Limited | ₹6.29 Lakh (FY 2024) | Lucknow, Uttar Pradesh, India | ||||
| Mufaasa Pharmaceuticals Private Limited | ₹6.28 Lakh (FY 2025) | Ahmedabad, Gujarat, India | ||||
| Vakker Pharmaceuticals Private Limited | ₹6.28 Lakh (FY 2025) | -6.0% | Ghaziabad, Uttar Pradesh, India |
To see the full peer comparison of Gemini Pharmaceuticals Limited, buy the company report.
Auditor
Gemini Pharmaceuticals Limited is audited by AGARWAL AJAY & ASSOCIATES for the financial year 2020.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| AGARWAL AJAY & ASSOCIATES | FY 2020 | 005159C |
Shareholding
The shareholding of Gemini Pharmaceuticals Limited is on record for 3 financial years, the latest being FY 2020, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2020 | FY 2017 | FY 2015 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Gemini Pharmaceuticals Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 04 May 2006 | 80032799 | State Bank of India | ₹5.27 Cr | Open |
To see the full charge records of Gemini Pharmaceuticals Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
Gemini Pharmaceuticals Limited has 9 court cases on record: 4 filed by Gemini Pharmaceuticals, 5 filed against it. 1 case is pending and 8 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 5 | 1 | 0 |
| District courts | 4 | 4 | 1 |
Cases on record (5 of 9)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Calcutta, West Bengal | Civil suit | Filed against the company by Ms Saf Fermion Ltd | Pending |
| High Court, UTTARAKHAND | Court case (WPMS) | Filed by the company against State Bank of India and Others | Disposed |
| High Court, UTTARAKHAND | Court case (SPA) | Filed by the company against State Bank of India and Others | Disposed |
| District court, South, Delhi | Execution petition | Filed against the company by Enrald Pharmachem | Disposed |
| High Court, UTTARAKHAND | Court case (WPMS) | Filed by the company against Union of India and Others | Disposed |
To see the full case history of Gemini Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Gemini Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Gemini Pharmaceuticals Limited has 1 active EPFO establishment as of Apr 07, 2024.
GST
No GST registration is on our record for Gemini Pharmaceuticals Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Gemini Pharmaceuticals Limited has 23 board changes on record since 2009: 4 appointments and 19 cessations. The latest: Anil Kumar ceased to be Additional Director on 31 Mar 2023.
16 earlier events are in the company report.
Frequently asked questions
Gemini Pharmaceuticals is an active public limited company based in Muzaffarnagar, Uttar Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 August 2005 (21+ years old) and is registered under CIN U24232UP2005PLC030446.
Gemini Pharmaceuticals has 4 current directors:
- Ramdev - Additional Director
- Kuwar Singh - Additional Director
- Sudhir Kumar - Director
- Ajay Kumar Sharma - Additional Director
The latest financial statements of Gemini Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Gemini Pharmaceuticals is U24232UP2005PLC030446. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Gemini Pharmaceuticals has 9 court cases on record: 4 filed by the company and 5 filed against it. 1 is pending. Most are in the high courts.
Gemini Pharmaceuticals was incorporated on 02 August 2005, making it 21+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.
The peers of Gemini Pharmaceuticals by revenue are Sitesh Kavya Formulations Private Limited, Himken Pharmaceuticals Private Limited, Healthelixir Pharmaceuticals Private Limited, Rangsubbs Pharmaceuticals (India) Private Limited, Galnmax Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Anil Kumar ceased to be Additional Director on 31 Mar 2023. Arun Kumar Gupta ceased to be Additional Director on 31 Mar 2023. Ruby Jha ceased to be Director on 31 Mar 2023. Gemini Pharmaceuticals has 23 board changes on record in total.
The registered office of Gemini Pharmaceuticals is at 19 – A New Mandi, Muzaffarnagar, Uttar Pradesh, India – 251001.
Gemini Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Gemini Pharmaceuticals has open charges of ₹5.27 Cr and no satisfied charges on record as per latest MCA filings.